慢性乙型肝炎、丙型肝炎及非酒精性脂肪性肝病（NAFLD）患者血浆尿激酶型纤溶酶原激活物受体（UPAR）作为血清纤维化标志物的评估

Evaluation of Plasma Urokinase-Type Plasminogen Activator Receptor (UPAR) in Patients With Chronic Hepatitis B, C and Non-Alcoholic Fatty Liver Disease (NAFLD) as Serological Fibrosis Marker.

作者信息

Akdoğan Özlem, Atak Yücel Ayşegül, Gök Sargin Zeynep, Sönmez Cemile, Esendağli Yilmaz Güldal, Özenirler Seren

机构信息

Department of Gastroenterology, Faculty of Medicine, Gazi University, Ankara, Turkey.

Department of Immunology, Faculty of Medicine, Gazi University, Ankara, Turkey.

出版信息

J Clin Exp Hepatol. 2019 Jan-Feb;9(1):29-33. doi: 10.1016/j.jceh.2018.02.001. Epub 2018 Feb 16.

DOI:10.1016/j.jceh.2018.02.001

PMID:30765936

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6363952/

Abstract

BACKGROUND/AIMS: Progressive hepatic fibrosis is the main predictor of outcome and prognosis in chronic liver diseases. The importance of the coagulation cascade has been defined in liver fibrosis; however, the role of the fibrinolytic pathway has not been clear yet. We aimed to evaluate the association between the plasma levels of soluble urokinase Plasminogen Activator Receptor (uPAR) and the severity of liver fibrosis in chronic hepatitis B, C and Non-Alcoholic Fatty Liver Disease (NAFLD).

METHODS

96 chronic hepatitis B, 22 chronic hepatitis C and 11 NAFLD patients together with 47 healthy controls were enrolled in the study. uPAR plasma levels were detected by Enzyme-Linked Immunosorbent Assay (ELISA) method.

RESULTS

The plasma levels of uPAR in patients with chronic hepatitis B and C significantly exceeded those of healthy controls ( < 0.001) while mean uPAR levels in patients with NAFLD were not different from healthy controls. Mean uPAR levels in chronic viral hepatitis patients with F1-F3 fibrosis and F4-F6 fibrosis were higher than those of control group ( < 0.001). Mean uPAR level in patients with F4-F6 fibrosis was significantly higher than that of patients with F1-F3 fibrosis ( < 0.001).

CONCLUSION

This is the first study that investigated uPAR as a fibrosis marker in NAFLD and chronic hepatitis B patients. It is suggested that plasma levels of uPAR are closely related to the fibrosis stage in chronic hepatitis B and C and that uPAR might be a noninvasive marker of liver fibrosis.

摘要

背景/目的：进行性肝纤维化是慢性肝病预后的主要预测指标。凝血级联反应在肝纤维化中的重要性已得到明确；然而，纤维蛋白溶解途径的作用尚不清楚。我们旨在评估慢性乙型肝炎、丙型肝炎和非酒精性脂肪性肝病（NAFLD）患者血浆中可溶性尿激酶型纤溶酶原激活物受体（uPAR）水平与肝纤维化严重程度之间的关联。

方法

本研究纳入了96例慢性乙型肝炎患者、22例慢性丙型肝炎患者和11例NAFLD患者以及47名健康对照者。采用酶联免疫吸附测定（ELISA）法检测uPAR血浆水平。

结果

慢性乙型肝炎和丙型肝炎患者的uPAR血浆水平显著高于健康对照者（<0.001），而NAFLD患者的uPAR平均水平与健康对照者无差异。F1 - F3纤维化和F4 - F6纤维化的慢性病毒性肝炎患者的uPAR平均水平高于对照组（<0.001）。F4 - F6纤维化患者的uPAR平均水平显著高于F1 - F3纤维化患者（<0.001）。